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Abstract. This study considers the clinical manifestations and risk factors of digoxin toxicity and
establishes an appropriate cut-off serum level for the diagnosis of toxicity. A retrospective study
of 125 hospitalized patients whose serum digoxin was assayed in 1998 was conducted. Of the 125
subjects, 42 (33.6%) were classified as having definite digoxin toxicity, 9 (7.2%) were classified
as having probable digoxin toxicity, and 74 (59.2%) were classified as non-toxicated. Of the
patients with definite digoxin toxicity, 24 (57.1%) had cardiac manifestations, seven (16.7%) had
non-cardiac manifestations, and 11 had manifestations of both types. The commonest manifesta-
tion was atrial fibrillation with block. Average daily doses of digoxin in the patients with definite
digoxin toxicity and those without intoxication varied from 0.125 to 0.5 ng/ml. There was no
significant statistical difference in digoxin dosage between those with and those without digoxin
toxicity. Seven univariate factors of digoxin toxicity were examined: logistic regression analysis
showed that, serum BUN and serum chloride were independent associated factors of digoxin
toxicity: the finding suggests that renal impairment and volume contraction are strong determi-
nants of digoxin toxicity. Mean (SD) serum digoxin levels among the patients with and without
toxicity were 2.28 (1.3) and 1.05 (0.6) ng/ml respectively (p = 0.000). The best cut-off level
determined by Receiver Operating Characteristic (ROC) analysis was 1.97 ng/ml. However, a
low sensitivity and a high specificity make serum digoxin levels a diagnostic rather than a
screening tool. The manifestations of digoxin toxicity among Thai inpatients are no different
from those of other populations. The best cut-off level of serum digoxin for the diagnosis of
toxicity is 2 ng/ml.
INTRODUCTION
Digoxin is commonly used in arrhythmia
and cardiac pumping failure; however, it often
cause adverse reactions (Tawakkol et al, 1967;
Smith et al, 1984). The effects of digoxin toxicity
are either cardiac and/or non-cardiac (Smith et
al, 1984; Mahdyoon et al, 1990). There have
been no reports of the effects of digoxin toxicity
in Thailand.
In clinical practice, the serum digoxin level
can be used to diagnose toxicity: a concentra-
tion of 2 ng/ml has been suggested as the cut-
off level (Smith et al, 1984); this recommended
cut-off value was adopted following various
studies of Caucasian patients. However, this
value has not been verified by a gold standard
(criterion validity); moreover, we do not know
whether the cut-off level is appropriate for the
diagnosis of digoxin toxicity among Thai
patients. This study was conducted to deter-
mine the effects of digoxin toxicity among Thai
medical in-patients; an appropriate cut-off level
for serum digoxin and the use of such a level
in clinical practice were also studied.
SUBJECTS AND METHODS
The sera of 125 subjects, who were
admitted to the medical department of the King
Chulalongkorn Memorial Hospital in 1998, were
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obtained and sent for measuring level of digoxin
by radioimmunoassay method; their medical
records were systematically reviewed. The
cardiac and non-cardiac manifestations of
digoxin toxicity were recorded; patients whose
manifestations resolved completely after the
discontinuation of digoxin were categorized as
definite digoxin toxicity; patients whose mani-
festations disappeared despite continued digoxin
or persisted after the discontinuation of digoxin
were categorized as non-toxication; the rest were
classified as probable digoxin toxicity.
Only the subjects with definite digoxin
toxicity and those non-intoxicated were further
analysed in order to establish an appropriate
cut-off level for, and the effects of, digoxin
toxicity.
Data regarding the average daily dose of
digoxin, indication for prescription, cardiac
disease, co-morbidity, other medicines, total
number of medicines, and laboratory data
including hematocrit, serum sodium, serum
potassium, serum chloride, serum bicarbonate,
serum blood urea nitrogen (BUN), serum
creatinine, serum albumin, serum globulin and
liver enzymes were collected.
Receiver Operating Characteristic (ROC)
analysis was used to identify the best cut-off
value. Sensitivity, specificity, positive predic-
tive value, negative predictive value, and like-
lihood ratio were computed. The unpaired t-
test and the chi-square test were used for
statistical analysis; univariate associated fac-
tors whose alpha errors were less than 5% were
subjected to logistic regression analysis. Odds
ratios and 95% confidence intervals were
computed. The SPSS-PC program (version 8.0)
was used.
RESULTS
The patients’ mean age (SD) was 58.7
(19.1) years; 48.8% were male. Forty-two
patients (33.6%) were classified as definite
digoxin toxicity (42.9% of these were male),
9 (7.2%) had probable digoxin toxicity (66.7%
of these were male), and 74 (59.2%) were non-
intoxicated (50% of these were male).
Indications for the use of digoxin atrial
fibrillation control (47.6% of intoxicated and
40.5% of non-intoxicated patients), pumping
failure treatment (21.4% of intoxicated and 27%
on non-intoxicated patients), both atrial fibril-
lation control and pumping failure treatment
(28.6% of intoxicated and 29.7% of non-in-
toxicated patients), and no definite indication
(2.4% of intoxicated and 2.7% of non-intoxi-
cated patients).
Of the patients with definite digoxin
toxicity, 24 (57.1%) had cardiac manifestations,
7 (16.7%) had non-cardiac manifestations, and
11 had both cardiac and non-cardiac manifes-
tations. The most common manifestation was
atrial fibrillation with block (Table 1).
The average daily doses of digoxin taken
by the patients with definite digoxin toxicity
and those non-intoxicated varied from 0.125
to 0.5 mg. Of the patients with definite digoxin
toxicity, 14 (33.3%) received 0.125 mg/day, 27
(64.3%) received 0.25 mg/day, and 1 (2.4%)
received 0.5 mg/day. Of the non-intoxicated
patients, 28 (37.8) received 0.125 mg/day, 44
(59.5%) received 0.25 mg/day, 1 (1.4%) received
0.375 mg/day, and 1 (1.4%) received 0.5 mg/
day. There was no significant statistical dif-
ference between the doses used by the patients
with and without toxicity.
Seven univariate factors of digoxin tox-
icity were considered: a history of renal dis-
ease, use of nitrates, use of furosemide, serum
blood urea nitrogen (BUN) above 20 mg/dl,
serum chloride below 85 mg/dl, serum crea-
tinine above 2 mg/dl, and hematocrit below 30%
(Table 2). Logistic regression analysis showed
that serum BUN (odds ratio = 2.9) and serum
chloride (all subjects with serum chloride < 85
mEq/l were classified as definite digoxin tox-
icity) were independent associated factors of
digoxin toxicity: of the patients with definite
digoxin toxicity, 66.7% had one or both of these
factors.
The mean (SD) of serum digoxin levels
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Table 1
Clinical manifestations of digoxin toxicity among 42 patients with definite digoxin toxicity.
Number % group % total
Cardiac manifestations 35 100.0 83.3
Sinus bradycardia 1 2.9 2.4
Sinus arrest 3 8.6 7.1
Sinus exit block 1 2.9 2.4
1st degree AV block 3 8.6 7.1
2nd degree AV block 1 2.9 2.4
3rd degree AV block 1 2.9 2.4
Atrial fibrilation with block 18 51.4 42.9
Non-paroxysmal junctional tachycardia 5 14.3 11.9
AV dissociation 1 2.9 2.4
Bi-directional ventricular tachycardia 1 2.9 2.4
Ventricular bigeminy 9 25.7 21.4
Ventricular tachycardia 1 2.9 2.4
Premature ventricular contraction 7 20.0 47.6
Non-cardiac manifestations 18 100.0 42.9
Nausea 7 38.9 16.7
Vomiting 9 50.0 21.4
Anorexia 5 27.8 11.9
Abdominal pain 4 22.2 9.5
Diarrhea 2 11.1 4.8
Fatigue 3 16.7 7.1
Dizziness 6 33.3 14.3
Visual disturbance 1 5.6 2.4
Headache 1 5.6 2.4
Table 2
Univariate factors of digoxin toxicity and their odds ratios (95% confidence intervals).
Number (%) among Number (%) among Odds ratios 95% confidence
definite group  non-intoxicated group  interval
Evidence of renal disease 9 (21.4) 5 (6.8) 3.8 1.2 - 12.1
Nitrate medication 17 (40.5) 15 (20.3) 2.7 1.2 - 6.2
Furosemide 33 (78.6) 43 (58.1) 2.6 1.1 - 6.3
Serum BUN > 20 mg/dl 25 (59.5) 26 (35.1) 2.7 1.2 - 5.9
Serum creatinine > 2 mg/dl 12 (28.6) 9 (12.2) 2.9 1.1 - 7.6
Serum chloride < 85 mEq/l 6 (14.3) - *
Hematocrit < 30% 11 (26.2) 8 (10.8) 2.9 1.1 - 8.0
* Odds ratio not computed because no non-intoxicated subject had serum chloride less than 85 mEq/l.
among the patients with and without toxicity
were 2.28 (1.3) and 1.05 (0.6) ng/ml respec-
tively (p = 0.000) (Fig 1). The serum digoxin
levels of those with definite toxicity varied from
0.21 ng/ml to ≥ 5 ng/ml; the levels of the non-
intoxicated patients varied from ≤ 0.2 ng/ml to
2.76 ng/ml. The best cut-off level determined
by ROC analysis was 1.97 ng/ml (Fig 2): the
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sensitivity was 0.62 and the specificity was 0.92.
Twenty-two subjects (10.3%) were therefore
misclassified an the basis of this cut-off level.
The positive and negative predictive values were
0.81 and 0.81 respectively; the likelihood ratio
for a positive test was 3.45.
DISCUSSION
This is the first study of Thai patients that
describes digoxin intoxication and evaluates the
validity of using a serum digoxin level for the
diagnosis of toxicity. Although there is general
concern about the limitations of retrospective
studies, problems reviewing records in this study
were few. Only 9 patients (7.2%) were clas-
sified as probable digoxin intoxication. Because
the doses of digoxin used by patients with
toxicity did not differ from those used by patients
without toxicity, the diagnosis of digoxin toxicity
cannot be reliant upon dosage.
The manifestations of digoxin toxicity
found in this study were not different from those
mentioned in other reports (Smith et al, 1984;
Mahdyoon et al, 1990). The cardiac manifes-
tations were common (83.3%), particularly atrial
fibrillation with block. However, 43% of the
subjects had non-cardiac manifestations: gas-
trointestinal symptoms and dizziness were
common. One in six of the subjects with digoxin
toxicity had only non-cardiac manifestations.
Associated factors of digoxin toxicity imply
an underlying pathogenesis, eg volume contrac-
tion, renal impairment, impaired myocyte
function, and poor general health (Smith et al,
1984). The results of logistic regression analy-
sis showed that high BUN and low serum
chloride were independent factors of digoxin
toxicity. This finding suggests that renal im-
pairment and volume depletion are strong risk
factors of digoxin toxicity among Thai patients.
Patients who are treated with digoxin and who
have these associated factors should be closely
monitored for digoxin toxicity.
Our findings support the use of a serum
digoxin level of ≥ 2 ng/ml as a cut-off level
(Smith et al, 1984; Smith, 1975; Doering et
al, 1977). However, there is an overlap of
therapeutic and toxic serum digoxin levels
(Beller et al, 1971; Smith et al, 1984); it needs
Fig 1–Serum digoxin level of patients with definite
digoxin toxicity, probable digoxin toxicity, and
non-intoxication.
Fig 2–Receiver Operating Characteristic (ROC) ana-
lysis of serum digoxin level for diagnosis of
digoxin toxicity.
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to be emphasized that nearly 20% of the patients
with positive results did not have digoxin toxicity
and nearly 20% of those with negative results
did have digoxin toxicity. Since the sensitivity
is rather low, the use of serum digoxin as a
screening tool is warrant. Its high specificity
and its likelihood ratio suggest that it would
serve better in the diagnosis of digoxin intoxi-
cation. Nevertheless, the serum level alone may
be of limited use in assisting clinicians to
establish a diagnosis of toxicity (Ingelfinger and
Goldman, 1976).
In conclusion, manifestations of digoxin
toxicity among Thai inpatients are no different
from those of other populations. The best cut-
off level of serum digoxin for the diagnosis
of toxicity is 2 ng/ml. The level of serum digoxin
should be used as a diagnostic tool rather than
as a screening tool. In order to avoid serious
adverse reactions, levels of serum digoxin must
be taken into account, along with all other
relevant clinical data, before management
decisions are made. Awareness of and regular
surveillance for the clinical-manifestation of
digoxin toxicity are central to good clinical
practice.
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